LEADER 01094nam0 2200313 450 001 000014325 005 20081216130928.0 010 $a0816211043 100 $a20080715d1976----km-y0itay50------ba 101 0 $aeng 102 $aUS 105 $ay-------001yy 200 1 $aTime series analysis$eforecasting and control$fGeorge E. P. Box and Gwilym M. Jenkins 205 $aRev. ed. 210 $aOakland (Cal.)$cHolden-Day$dc1976 215 $aXXI, 575 p.$d24 cm 225 2 $aHolden-Day series in time series analysis and digital processing 410 0$12001$aHolden-Day series in time series analysis and digital processing 500 10$aTime series analysis$935369 610 1 $aSerie temporali 676 $a519.55$v20$9Matematica statistica. Analisi di serie temporali 700 1$aBox,$bGeorge E. P.$030397 701 1$aJenkins,$bGwilym M.$013805 801 0$aIT$bUNIPARTHENOPE$c20080715$gRICA$2UNIMARC 912 $a000014325 951 $a211.1/125$b5417$cNAVA2$d2008 951 $aG 519.55/1$bG 882$cDSA$d2008 996 $aTime series analysis$935369 997 $aUNIPARTHENOPE LEADER 02933nam 2200337z- 450 001 996320739703316 005 20231214133444.0 035 $a(CKB)5340000000058072 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/71145 035 $a(EXLCZ)995340000000058072 100 $a20202107d2018 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPerspectives on treating hypertension in old age$eThe burden of polypharmacy, risks of treatment and GPs? treatment probability 210 $aRotterdam$cOPTIMA$d2018 311 $a94-6361-126-6 330 $aWith increasing age, blood pressure rises as a consequence of arterial stiffness and it has been debated whether or not to it is beneficial to treat hypertension in old age especially in >75-year-olds when they have multimorbidity, polypharmacy or frailty. Large hypertension trials showed that lowering SBP in >60-year-olds is beneficial and lowers the risk for myocardial infarction, stroke and all-cause mortality, even in >80-year-olds. However, these trials lack generalizability and typically excluded multimorbid patients that are frail. At the same time, observational studies rose concerns about lowering SBP too much since there are several cohort studies showing a reverse association of low SBP and increased mortality and accelerated cognitive decline especially in >75-year-olds. However, current hypertension guidelines advise physicians to lower SBP to values of even <130mmHg in all patients from the age of 60 years, which fuelled the discussions about the benefits and harms of lowering SBP too much in >75-year-olds under antihypertensive treatment especially when they are frail defined as having low hand grip strength or complex health problems in multiple domains of daily living. The general aim of this thesis is to increase the scientific knowledge about the effects of treating hypertension in >75-year-olds with frailty. This thesis has three aims: 1) to measure the prevalence of polypharmacy in older patients; 2) to test for an association between low SBP and mortality, cognitive function, daily functioning, and QoL in older patients under antihypertensive treatment; and 3) to understand the role that frailty plays in GP decisions about treating hypertension in old age across countries and see if those differences can be explained by country-specific cardiovascular disease burden and life expectancy. 517 $aPerspectives on treating hypertension in old age 606 $aCardiovascular medicine$2bicssc 610 $aHypertension 610 $aOld Age 610 $aFraitly 615 7$aCardiovascular medicine 700 $aStreit$b Sven$4auth$0988614 906 $aBOOK 912 $a996320739703316 996 $aPerspectives on treating hypertension in old age$92992010 997 $aUNISA